Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

被引：68
作者：
Freidlin, Boris [1 ]
Korn, Edward L. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 35期
关键词：
LIVED SIGNIFICANTLY LONGER; ASSESS TREATMENT EFFICACY; MEAN SURVIVAL-TIME; EVALUATING NONINFERIORITY; INTERPRETABLE STATISTICS; DISCONTINUED TREATMENT; ADVANCED MELANOMA; ADJUVANT THERAPY; VERSATILE TESTS; CANCER;
D O I：
10.1200/JCO.19.01681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3455 / +
页数：7
相关论文
共 58 条
  • [1] Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
    A'Hern, Roger P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3474 - +
  • [2] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [3] Neratinib after trastuzumab in patients with HER2-positive breast cancer Reply
    Chan, Arlene
    Buyse, Marc
    Yao, Bin
    [J]. LANCET ONCOLOGY, 2016, 17 (05) : E176 - E177
  • [4] Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Chan, Arlene
    Delaloge, Suzette
    Holmes, Frankie A.
    Moy, Beverly
    Iwata, Hiroji
    Harvey, Vernon J.
    Robert, Nicholas J.
    Silovski, Tajana
    Gokmen, Erhan
    von Minckwitz, Gunter
    Ejlertsen, Bent
    Chia, Stephen K. L.
    Mansi, Janine
    Barrios, Carlos H.
    Gnant, Michael
    Buyse, Marc
    Gore, Ira
    Smith, John, II
    Harker, Graydon
    Masuda, Norikazu
    Petrakova, Katarina
    Guerrero Zotano, Angel
    Iannotti, Nicholas
    Rodriguez, Gladys
    Tassone, Pierfrancesco
    Wong, Alvin
    Bryce, Richard
    Ye, Yining
    Yao, Bin
    Martin, Miguel
    [J]. LANCET ONCOLOGY, 2016, 17 (03) : 367 - 377
  • [5] Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
    Chen, Tai-Tsang
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (09):
  • [6] Statistical issues and challenges in immuno-oncology
    Chen, Tai-Tsang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2013, 1
  • [7] There is still a place for significance testing in clinical trials
    Cook, Jonathan A.
    Fergusson, Dean A.
    Ford, Ian
    Gonen, Mithat
    Kimmelman, Jonathan
    Korn, Edward L.
    Begg, Colin B.
    [J]. CLINICAL TRIALS, 2019, 16 (03) : 223 - 224
  • [8] Duke University, PUBL WORKSH ONC CLIN
  • [9] Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer Reply
    Eisenberger, Mario A.
    Zhang, Wenping
    Shun, Zhenming
    de Bono, Johann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 826 - +
  • [10] Fang XM, 2018, JAMA ONCOL, V4, P743, DOI 10.1001/jamaoncol.2017.3983
123456